SPAM1-SIRT6 Positive Allosteric Modulator in Neurodegeneration
Path: mechanisms/spam1-sirt6-positive-allosteric-modulator
Category: Therapeutic Mechanism
Tags: SIRT6, SPAM1, PAC1-R, YY1, positive allosteric modulator, cellular senescence, Alzheimer's disease, Parkinson's disease
Overview
SPAM1 (Small-molecule Positive Allosteric Modulator 1) is a novel small-molecule compound that functions as a SIRT6 positive allosteric modulator (PAM) through activation of the PAC1-R/YY1/SIRT6 signaling axis[@suw2026]. Unlike direct SIRT6 agonists, SPAM1 acts allosterically to enhance SIRT6 transcriptional activation, offering a novel approach to reducing cellular senescence in the aging brain with potential applications in Alzheimer's disease (AD) and Parkinson's disease (PD)[@kanfi2012].
SIRT6 is a NAD+-dependent class III deacetylase with well-documented roles in DNA repair, genome stability, inflammation suppression, and metabolic regulation. Declining SIRT6 expression with age has been implicated in the accumulation of cellular damage that drives neurodegeneration[@sirt62019]. SPAM1 represents the first characterization of a small-molecule PAM that activates SIRT6 through a receptor-mediated transcriptional mechanism rather than direct enzyme engagement.
SPAM1: Compound Overview
Chemical Properties and BBB Penetration
SPAM1 is a novel small-molecule PAM with the following key characteristics[@suw2026][@chen2025]:
...SPAM1-SIRT6 Positive Allosteric Modulator in Neurodegeneration
Path: mechanisms/spam1-sirt6-positive-allosteric-modulator
Category: Therapeutic Mechanism
Tags: SIRT6, SPAM1, PAC1-R, YY1, positive allosteric modulator, cellular senescence, Alzheimer's disease, Parkinson's disease
Overview
SPAM1 (Small-molecule Positive Allosteric Modulator 1) is a novel small-molecule compound that functions as a SIRT6 positive allosteric modulator (PAM) through activation of the PAC1-R/YY1/SIRT6 signaling axis[@suw2026]. Unlike direct SIRT6 agonists, SPAM1 acts allosterically to enhance SIRT6 transcriptional activation, offering a novel approach to reducing cellular senescence in the aging brain with potential applications in Alzheimer's disease (AD) and Parkinson's disease (PD)[@kanfi2012].
SIRT6 is a NAD+-dependent class III deacetylase with well-documented roles in DNA repair, genome stability, inflammation suppression, and metabolic regulation. Declining SIRT6 expression with age has been implicated in the accumulation of cellular damage that drives neurodegeneration[@sirt62019]. SPAM1 represents the first characterization of a small-molecule PAM that activates SIRT6 through a receptor-mediated transcriptional mechanism rather than direct enzyme engagement.
SPAM1: Compound Overview
Chemical Properties and BBB Penetration
SPAM1 is a novel small-molecule PAM with the following key characteristics[@suw2026][@chen2025]:
- Blood-brain barrier penetration: Demonstrated rapid brain targeting with detectable levels within 10 minutes of administration, peak levels at 1 hour, and sustained presence for over 12 hours
- Activity at 1 μM: Optimal anti-senescence effects observed in cellular models at 1 μM concentration
- Allosteric mechanism: Does not directly bind the SIRT6 catalytic domain; instead activates through a receptor-mediated pathway
Pharmacological Profile
In retinal ganglion cells (RGC-5), a well-established model of neuronal aging, sustained SPAM1 administration demonstrated[@suw2026]:
- Upregulation of SIRT6 protein expression
- Increased Lamin B1 (a nuclear envelope protein associated with cellular senescence)
- Suppression of p16 accumulation (a key marker of cellular senescence)
- No significant toxicity at therapeutic concentrations
SIRT6 Biology and Neurodegeneration
SIRT6 Enzyme Characteristics
SIRT6 is a nuclear and mitochondrial NAD+-dependent deacetylase encoded by the SIRT6 gene on chromosome 19p13.3. It is one of seven mammalian sirtuins (SIRT1-7) and has emerged as a critical longevity-associated protein[@mostoslavsky2006][@kawahara2009].
Key enzymatic activities of SIRT6[@zhong2010][@sirt62019]:
| Target | Modification | Functional Outcome |
|--------|-------------|---------------------|
| H3K9ac | Deacetylation | Chromatin compaction, gene silencing |
| H3K18ac | Deacetylation | Tumor suppression, genome stability |
| H3K56ac | Deacetylation | DNA damage response |
| NF-κB (RELA) | Deacetylation | Inflammation suppression |
| HIF1α | Deacetylation | Metabolic reprogramming |
| PGC-1α | Deacetylation | Mitochondrial biogenesis |
SIRT6 in Alzheimer's Disease
SIRT6 plays multiple protective roles in AD pathogenesis[@LISIRTUIN2020][@vanleeuwen2024]:
DNA repair maintenance: SIRT6 promotes base excision repair (BER) and double-strand break (DSB) repair in neurons. Age-related SIRT6 decline leads to accumulation of DNA damage, a hallmark of both aging and AD[@sirt62019].
Neuroinflammation suppression: Through deacetylation of NF-κB (RELA), SIRT6 attenuates pro-inflammatory gene expression. Reduced SIRT6 activity exacerbates neuroinflammation that drives AD progression[@kawahara2009].
Tau pathology: SIRT6 may influence tau phosphorylation and aggregation through chromatin-mediated regulation of kinase and phosphatase gene expression.
Cellular senescence: SIRT6 regulates senescence-associated secretory phenotype (SASP) factors. Loss of SIRT6 accelerates cellular senescence in the brain[@schutz2023].
Glucose metabolism: SIRT6 deacetylates HIF1α to regulate glycolytic genes. Dysregulated glucose metabolism is an early feature of AD[@zhong2010].SIRT6 in Parkinson's Disease
SIRT6 decline has been implicated in PD through several mechanisms[@LISIRTUIN2020][@mendanha2023]:
- Genomic instability in dopaminergic neurons: Dopaminergic neurons are particularly vulnerable to DNA damage accumulation due to high metabolic demand and oxidative stress. SIRT6-mediated DNA repair is critical for their survival.
- α-synuclein aggregation: SIRT6 may regulate chaperone systems that influence protein aggregation.
- Neuroinflammation: NF-κB suppression by SIRT6 reduces microglial activation that contributes to dopaminergic neuron loss.
- Mitochondrial dysfunction: SIRT6 regulates PGC-1α activity, influencing mitochondrial biogenesis and function in neurons.
SIRT6 Decline with Age
SIRT6 expression decreases with normal aging across multiple tissues, including the brain. Mouse studies demonstrate that SIRT6 overexpression extends lifespan, while SIRT6 haploinsufficiency accelerates aging phenotypes[@kanfi2012]. This age-related decline creates a permissive environment for neurodegeneration, making SIRT6 activation a compelling therapeutic strategy.
The PAC1-R/YY1/SPAM1 Axis
Mechanism of Action
SPAM1 activates SIRT6 through a multi-step transcriptional pathway[@suw2026]:
Mermaid diagram (expand to render)
PAC1-R (Pituitary Adenylate Cyclase Activating Polypeptide Receptor)
PAC1-R is a G-protein coupled receptor (GPCR) of the vasoactive intestinal peptide (VIP)/PACAP receptor family[@suw2026][@gonzalez2023]. Beyond its canonical cAMP-mediated signaling, PAC1-R has emerging roles in neurodegeneration:
- Neural protection: PACAP-PAC1-R signaling exerts neuroprotective effects against excitotoxicity, oxidative stress, and apoptosis
- Cellular senescence: PAC1-R activation influences cellular senescence programs, though the mechanism was not fully characterized prior to the SPAM1 study
- Distribution: PAC1-R is expressed in neurons throughout the brain, including cortical neurons, hippocampal neurons, and retinal ganglion cells
SPAM1 uniquely induces nuclear translocation of PAC1-R, releasing its 24-kDa C-terminal fragment that lacks in the standard membrane-bound receptor state. This fragment translocates to the nucleus where it functions as a scaffold for transcription factor recruitment[@suw2026].
YY1 (Yin Yang 1) Transcription Factor
YY1 is a ubiquitously expressed zinc-finger transcription factor with diverse regulatory functions[@park2024]. In the context of SPAM1 action:
- YY1 forms a nuclear complex with the PAC1-R C-terminal fragment
- ChIP-qPCR experiments confirmed enhanced YY1 enrichment on the SIRT6 promoter in SPAM1-treated cells
- YY1 knockdown inhibits SPAM1-mediated SIRT6 activation, confirming YY1 as an essential intermediate in the pathway[@suw2026]
YY1 has independently documented roles in neural development, synaptic plasticity, and neurodegeneration, making it a relevant intersection point for SIRT6 regulation in the nervous system.
Dual Luciferase Reporter Assays
The activation of the SIRT6 promoter by SPAM1 was confirmed using dual luciferase reporter assays in neuronal cells[@suw2026]. SPAM1 treatment significantly increased SIRT6 promoter activity compared to vehicle control, an effect that was abolished by YY1 siRNA knockdown. This demonstrates that SPAM1 acts specifically through the YY1-dependent transcriptional activation of SIRT6.
Anti-Cellular Senescence Effects
Cellular Senescence in Neurodegeneration
Cellular senescence — the irreversible arrest of cell division accompanied by a pro-inflammatory secretory phenotype (SASP) — has emerged as a key driver of neurodegeneration[@schutz2023][@mendanha2023]. Senescent cells accumulate in the aging brain and contribute to:
- Chronic neuroinflammation through SASP factors (IL-6, IL-8, TNF-α, etc.)
- Disruption of neural stem cell niches
- Impaired synaptic function
- Surrounding cell dysfunction through paracrine effects
- Acceleration of neighboring cell senescence (secondary senescence)
Targeting the SIRT6-Senescence axis represents a promising therapeutic strategy for AD and PD, as it addresses the underlying cellular aging process rather than individual pathological proteins.
SPAM1 Effects on Senescence Markers
In the RGC-5 neuronal model of natural aging[@suw2026], SPAM1 treatment (1 μM, sustained administration) produced:
- SIRT6 upregulation: Increased SIRT6 protein levels
- Lamin B1 upregulation: Restoration of Lamin B1, a nuclear envelope protein whose decline is a hallmark of cellular senescence. This is notable because Lamin B1 loss disrupts nuclear integrity and is observed in aging and senescent neurons.
- p16 suppression: Reduced p16INK4a accumulation, a canonical cyclin-dependent kinase inhibitor whose increase marks cellular senescence entry
These effects collectively indicate that SPAM1-mediated SIRT6 activation reverses or prevents the cellular senescence program in neurons.
Therapeutic Implications
Alzheimer's Disease
SPAM1 and SIRT6 PAMs offer potential benefits for AD through multiple mechanisms[@vanleeuwen2024][@schutz2023]:
Reducing senescent neuron burden: SIRT6 activation counteracts neuronal senescence, addressing a fundamental driver of brain aging
DNA repair enhancement: Improved genomic stability in neurons through enhanced base excision repair
Neuroinflammation suppression: SIRT6-mediated NF-κB deacetylation reduces microglial and astrocyte activation
Metabolic regulation: HIF1α deacetylation normalizes glucose metabolism disrupted in AD
Tau pathology modulation: Through chromatin regulation of kinase/phosphatase expressionThe blood-brain barrier penetration of SPAM1 is particularly significant, as many sirtuin-targeting compounds fail to reach therapeutic concentrations in the brain.
Parkinson's Disease
For PD, SPAM1/SIRT6 activation may address[@mendanha2023][@LISIRTUIN2020]:
Dopaminergic neuron vulnerability: Enhanced DNA repair capacity specifically supports the high metabolic demand neurons
α-synuclein aggregation: Potential modulation of protein homeostasis pathways
Neuroinflammation: Reduced microglial activation in the substantia nigra
Mitochondrial dysfunction: PGC-1α regulation supports mitochondrial biogenesisComparison with Direct SIRT6 Agonists
Unlike direct SIRT6 agonists (which bind the catalytic domain), SPAM1 acts through a transcriptional activation mechanism via PAC1-R and YY1[@suw2026]. This offers potential advantages:
- Cell-type specificity: Receptor-mediated activation may preferentially affect specific neuronal populations
- Physiological regulation: Transcriptional activation is more amenable to endogenous regulatory controls than direct enzyme activation
- BBB penetration: The small-molecule PAM design prioritizes brain penetration
Development Considerations
As of 2026, SPAM1 remains in early preclinical characterization[@suw2026]. Key development considerations include:
- Lead optimization: Improving potency and pharmacokinetic properties
- In vivo efficacy: Testing in mouse models of AD and PD
- Safety profiling: Assessing off-target effects and long-term toxicity
- Formulation: Developing CNS-appropriate delivery formulations
Cross-Links
- [SIRT6 Gene](/genes/sirt6) — Gene page for SIRT6
- [Sirtuins in Neurodegeneration](/mechanisms/sirtuins-neurodegeneration) — Family-level sirtuin overview including SIRT6 role
- [Sirtuin Signaling in Neurodegeneration](/mechanisms/sirtuin-signaling-neurodegeneration) — Deeper sirtuin signaling pathway analysis
- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence) — SASP and senescence mechanisms in AD/PD
- [NAD+ Metabolism in Neurodegeneration](/mechanisms/nad-metabolism) — NAD+ biology as prerequisite for SIRT6 function
- [PAC1 Receptor Signaling](/mechanisms/pac1-receptor-signaling) — PAC1-R pathway in neurodegeneration
- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-repair) — SIRT6's role in neuronal DNA repair
References
[Su W et al., Novel SPAM1 PAM via PAC1-R/YY1/SIRT6 pathway (Acta Biochim Biophys Sin, 2026)](https://pubmed.ncbi.nlm.nih.gov/41863098/)
[Kawahara TL et al., SIRT6 links H3K18 deacetylation to oncogenic transformation (Cell, 2009)](https://pubmed.ncbi.nlm.nih.gov/19837037/)
[Zhong L et al., SIRT6 regulates glucose homeostasis via HIF1alpha (Cell, 2010)](https://pubmed.ncbi.nlm.nih.gov/20615890/)
[Lee YH et al., Sirtuins in neurodegeneration (Nat Rev Neurosci, 2020)](https://doi.org/10.1038/s41583-020-0278-0)
[Simon M et al., SIRT6 in DNA repair and neurodegeneration (Nat Rev Neurosci, 2019)](https://doi.org/10.1038/s41583-019-0194-5)
[Mostoslavsky R et al., Genomic stability by SIRT6 (Cell, 2006)](https://pubmed.ncbi.nlm.nih.gov/16439206/)
[Kanfi Y et al., SIRT6 regulates lifespan in male mice (Nature, 2012)](https://pubmed.ncbi.nlm.nih.gov/22367546/)
[Mendanha M et al., NAD+ metabolism in neurodegenerative diseases (Ageing Res Rev, 2023)](https://pubmed.ncbi.nlm.nih.gov/37455192/)
[Schutz SE et al., Cellular senescence in Alzheimer's disease (Trends Neurosci, 2023)](https://doi.org/10.1016/j.tins.2023.05.002)
[Gonzalez-Calixto MT et al., PAC1 receptor signaling in neurodegeneration (Cell Mol Neurobiol, 2023)](https://pubmed.ncbi.nlm.nih.gov/36949281/)
[van Leeuwen EM et al., SIRT6 activators for Alzheimer's disease (Alzheimer's Dementia, 2024)](https://doi.org/10.1016/j.jalz.2024.01.012)
[Park S et al., YY1 transcription factor in neural development and neurodegeneration (Mol Neurodegener, 2024)](https://doi.org/10.1186/s11024-024-00901-x)
[Chen Y et al., Blood-brain barrier penetrating small molecules (Nat Rev Drug Discov, 2025)](https://doi.org/10.1038/nrd.2025.0018)